Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients

• Prif Awduron: I. H. Bartelink (Awdur), E. A. van de Stadt (Awdur), A. F. Leeuwerik (Awdur), V. L. J. L. Thijssen (Awdur), J. R. I. Hupsel (Awdur), J. F. van den Nieuwendijk (Awdur), I. Bahce (Awdur), M. Yaqub (Awdur), N. H. Hendrikse (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: MDPI AG, 2022-06-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Introduction: Epidermal growth factor receptor (EGFR) mutated NSCLC is best treated using an EGFR tyrosine kinase inhibitor (TKI). The presence and accessibility of EGFR overexpression and mutation in NSCLC can be determined using radiolabeled EGFR TKI PET/CT. However, recent research has shown a si...